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Abstract 
Herpes simplex virus type 1 (HSV-1) is a common human herpesvirus that has a sero-
prevalence between 70-80% in the adult population and can lead to oral/genital lesions 
and viral encephalitis. Infected cell protein (ICP) 27 (ICP27) is an essential, 512-residue 
HSV-1 protein that performs many different functions during infection including but not 
limited to the regulation of viral gene expression, participating in viral mRNA export and 
modulating the cellular interferon response pathway. The majority of previous studies of 
this viral protein have been conducted in Vero cells, a line of African green monkey 
kidney cells. Here we have examined the phenotype of viral ICP27 mutants in other cell 
lines and primary cultures. We identified one mutant, d1-2, which shows a striking cell 
type-dependent growth defect in that it can partially replicate in Vero cells and some 
other cells but cannot replicate at all in many human cells including primary fibroblasts. 
Analysis of d1-2 infections showed that its restricted replication is associated with 
markedly decreased expression of the viral ICP8 gene and aberrant formation of viral 
replication compartments. These data suggest that viral DNA replication is tightly 
blocked in restrictive cells. Using a plasmid transfection/virus complementation strategy, 
we demonstrate that the cell-type dependent replication phenotype of HSV-1 mutants 
maps to the N-terminus of ICP27, specifically to residues 12-20. Together, our data 
indicate that ICP27 function is dependent on host cell type and that HSV-1 studies in 
Vero cells may not fully model natural human infections.  
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INTRODUCTION 
HSV-1 and the HSV-1 replication cycle. 
 Herpes Simplex Virus 1 or HSV-1, is an enveloped alphaherpesvirus with a 
dsDNA genome of approximately 150 kb (1, 2)  It is an ubiquitous human pathogen with 
a seroprevalence that increases from childhood, reaching 70%-80% in adolescence. The 
major route of transmission is through saliva which leads to infection of epithelial cells, 
although there are alternative routes including transplacental and blood-borne transfer. In 
epithelial cells, the virus undergoes a lytic infection phase. The virus then spreads to the 
peripheral nervous system where it establishes a latent permanent infection in ganglia.  
While typically associated with non-life threatening oral and genital lesions, more severe 
pathology is possible. For example, HSV-1 is the most common cause of viral 
encephalitis in non-tropical areas and its incidence is estimated to be one case per million 
people per year (2).   
HSV-1 Replication Cycle 
 The HSV-1 replication cycle begins through the action of several viral envelope 
proteins including at least glycoprotein B (gB), gC, gD,  and a gH/gL heterodimer with 
the host cell membrane (3, 4). This initial interaction is mediated by the binding of gC to 
heparin sulfate moieties on the host cell surface. Virion attachment is then stabilized 
through interaction between gD and one of several possible cellular receptors collectively 
identified as Herpes virus entry (Hve) proteins. There are two protein families of which 
these cellular receptors are members: the tumor necrosis factor (TNF) family which 
includes HveA, and the immunoglobulin superfamily which includes HveB, HveC, and 
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HIgR. Fusion is proposed to be facilitated by gD binding to several of its cognate 
receptors including nectin-1, herpes virus entry mediator, and immunoglobulin-like type 
2 receptor alpha (PILRα) (3). gD binding is next posited to trigger sequential 
conformational changes in gH/gL and gB, facilitating viral envelope fusion with the cell 
membrane (3). Following entry, the viral nucleocapsid and tegument proteins are released 
into the host cell cytoplasm. The nucleocapsid, along with tegument proteins VP16 and 
VP1-2, are carried to the nucleus by the microtubule network, while some tegument 
proteins such as vhs and US11 stay in the cytoplasm.      
 Once the HSV-1 DNA enters the nucleus, transcription of viral genes by host 
RNA polymerase II begins. HSV-1 gene expression and its regulation by various gene 
products have been studied extensively (5–9). HSV-1 viral gene expression consists of 
three phases that occur sequentially, leading to the production of immediate-early (IE or 
α), delayed-early (DE or β), and late (L or γ) gene products. In general, IE proteins, 
including ICP0, ICP4, ICP22, and ICP27, regulate the viral gene expression cascade; E 
proteins mediate viral DNA replication; and L proteins are structural proteins or proteins 
involved in assembly and maturation of virions.  
 HSV-1 protein synthesis is not required for IE transcription (10). Transcription of 
the IE genes occurs through recruitment of cellular transcriptional machinery to IE gene 
promoters. The tegument protein VP16 enhances IE gene expression through its 
interactions with HCF and Oct-1. Specifically, VP16 interacts with HCF in the cytoplasm 
and is translocated to the nucleus where it binds cellular protein Oct-1. This complex 
binds to the viral DNA at consensus TAATGArATT sites upstream of the RNA cap site. 
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This VP16 and Oct-1 complex enhances transcription of the IE genes by recruiting 
general transcription factors including TFIIB, TFIIH, TATA-binding protein, and TBP-
associated factors (1). This interaction leads to the formation of the RNA pol II pre-
initiation complex on IE promoters. 
 The IE gene proteins ICP4, ICP0, and ICP27 promote the expression of DE genes 
(6, 7, 9, 11, 12). ICP4 interacts with various cellular transcription factors to activate DE 
gene expression (12). ICP27, as will be discussed in more detail later, acts at both the 
transcriptional and posttranscriptional level to regulate the synthesis of some DE proteins 
(6, 7, 9, 11, 12). ICP0 interacts with cellular proteins to activate transcription and create a 
cellular environment suitable for viral replication (13). 
 Three IE proteins (ICP4, ICP0, and ICP27) are needed for expression of L genes, 
which are divided into two classes: leaky-late or γ1, and true-late or γ2 (6, 14–20). 
Expression of leaky late proteins can occur in the absence of viral DNA replication, but 
levels of these proteins are increased upon initiation of DNA replication. The true-late are 
only transcribed after viral DNA replication begins. 
 At the same time that it induces viral gene expression, HSV-1 shuts down host 
cell mRNA and protein synthesis through the action of a number of viral proteins 
including viral host shutoff protein (vhs) protein (15, 21, 22). Vhs facilitates the 
degradation of cellular mRNAs. ICP27 also has a role in host shutoff as will be discussed 
below. Another IE protein, ICP22, modifies host RNA polymerase II, possibly enhancing 
its ability to transcribe the viral genome at the expense of host genome transcription (23–
28).  
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 HSV-1 DNA replication takes place in the nucleus of infected cells in specialized 
structures called replication compartments (29). These structures form adjacent to cellular 
ND10 sites and then mature into replication compartments as viral DNA synthesis 
begins. Viral DNA replication can be initiated at any of three origins of replication on the 
HSV genome and is suggested to initially proceed via a theta replication mechanism (30). 
However, after DNA synthesis initiation, a rolling-circle mechanism likely comes into 
play to generate progeny genomes in the form of head-to-tail concatemers.  
 There are seven HSV-1 genes that are essential for viral DNA replication (31–42). 
The protein products of these seven genes are an origin binding protein (UL9), a single-
stranded DNA binding protein ICP8 (UL29), a helicase-primase complex 
(UL5/UL8/UL52), and a DNA polymerase (UL30/UL42) (4). Cellular factors including 
DNA ligases and topoisomerases likely also assist in viral DNA replication. UL9 binds as 
a homodimer to the origin of replication at sites that contain the DNA sequence 
CGTTCGCACTT (33, 36). This leads to a bend in the DNA that distorts the DNA 
structure into a single-stranded stem loop structure. The ssDNA and UL9 are suggested to 
recruit ICP8, which then stimulates the helicase activity of UL9 . ICP8 is essential for 
viral DNA synthesis and has not only been shown to stimulate the helicase activity of 
UL9, but also to promote the helicase-primase complex and to modify the polymerase 
activity of UL30 (33). Furthermore, ICP8 is required for viral replication compartment 
formation (33). The multifunctionality of ICP8 and its interaction with numerous viral 
replication proteins have led to the suggestion that it is a scaffolding protein able to 
recruit replication proteins to proper sites in the nucleus (33, 34, 37).  
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 Viral capsid assembly requires synthesis of a number of late structural proteins 
and occurs within the nucleus (43–46). The mature HSV-1 capsid consists of an outer 
shell that has penton-shaped subunits of the major capsid protein, VP5, and hexons of 
VP5 and VP23. Capsid assembly can occur without any assistance from cellular factors, 
as this has been observed in vitro using purified viral protein components (46). Viral 
DNA is packaged in genome-length monomers forming the nucleocapsid. DNA cleavage 
and packaging are not completely understood, but a number of viral gene products are 
known to be involved in this process (47–50).  
 Virion envelopment proceeds through a process involving two envelopment steps 
(51–54). The initial nucleocapsid buds through the inner nuclear membrane where it 
receives some tegument proteins and a primary envelope. Next, the primary enveloped 
virion fuses with the outer nuclear membrane, and the free nucleocapid is released into 
the cytoplasm where it is re-enveloped by budding into the trans-Golgi network. These 
re-enveloped virions are then secreted in vesicles to the extracellular environment 
through the process of exocytosis.             
The Multifunctional ICP27 Protein:  
Physical Properties of the Protein 
 ICP27 is an HSV-1 protein with a predicted mass of 52 kDa. It is comprised of 
512 amino acid residues (Fig. 1). On SDS-PAGE, ICP27 migrates as a 63 kDa protein 
(55, 56). The discrepancy between its predicted molecular weight and its observed size 
on SDS-PAGE may be due in part to the fact that it is extensively post-translationally 
modified as described below.  
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 The best characterized post-translational modification that ICP27 undergoes is 
phosphorylation. Phosphorylation can regulate protein activities and interactions. A study 
by the Sandri-Goldin lab showed that mutation of ICP27 phosphorylation sites led to 
decreases in viral growth, DNA replication, and the transcription of an early and late gene 
(57). Three phosphorylation sites were shown to be important: serine residues 16 and 18, 
which are potential casein kinase 2 sites, and serine residue 114, which is a potential 
protein kinase A site (57). It is likely there are other functionally important 
phosphorylation sites that have not been uncovered yet. 
 A second form of ICP27 post-translational modification is methylation of three 
arginines in the RGG box sequence, at residues 138, 148, and 150 (5, 58–62). This region 
is responsible for ICP27’s ability to bind RNA and to act as an export adaptor for HSV-1 
mRNA (5, 58–61, 63, 64). In an arginine-to-lysine substitution experiment, mutant forms 
of ICP27 were unable to bind the cellular proteins Aly/REF and SRPK1 and the viruses 
harboring these mutations were deficient in viral replication and growth (59).  
RNA-binding activity 
 The RNA-binding activity of ICP27 was originally identified by Mears and Rice 
using a RNA homo-polymer binding assay (61). ICP27 was found to bind strongly to 
poly(G).  The RNA-binding activity was mapped to an RGG box motif composed of 15 
arginine and glycine residues. Mears and Rice also determined that the RGG box domain 
is essential for ICP27 biological function as a recombinant HSV-1 lacking an RGG box 
does not replicate efficiently in culture (65). Further work showed that  the RGG box 
domain does not bind RNA G-quartet structures but rather interacts with flexible GC-rich 
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sequences (61, 62). Corbin-Lickfett et al. proposed that this preference for high GC 
content may allow ICP27 to distinguish between viral and cellular mRNA, given that the 
HSV-1 genome is 68% GC while the cellular genome is approximately 44% GC (62).  
They also suggested that ICP27's preference for flexible sequences may prevent it from 
interacting with some GC-rich cellular sequences, such as rRNAs which are highly 
structured. Consistent with these in vitro studies, Sandri-Goldin et al. found that ICP27 
binds to viral mRNAs in vivo and that most of these targets are intronless (66).  
Evidence for flexible structure 
 As will be discussed later, ICP27 interacts with a variety of cellular and viral 
proteins. Although many cellular and viral proteins have defined tertiary structures, 
recent studies indicate that other proteins, particularly those that interact with numerous 
partners, can be intrinsically disordered or have long, disordered regions (67). Consistent 
with this, NMR and bioinformatics studies have shown that N-terminal region of ICP27 
has a high degree of flexibility and disorder (68). The disordered N-terminal region of 
ICP27 consists of a 160 amino acid region containing the leucine-rich nuclear export 
sequence, nuclear localization signal, and the RGG box (68). Several different partners of  
ICP27 bind in this region including RNA polymerase II, TAP/NXF1, Hsc70, Aly/REF, 
SRPK1, and RNA (68).  
Functions: induction of E and L gene expression 
 Over the years, it has become clear that ICP27 is a multifunctional protein. This 
and the following sections summarize functions that have been attributed to ICP27.  
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 ICP27 has a number of important functions relating to the regulation of viral gene 
expression. Importantly, ICP27 induces the expression of many of the E and L viral 
genes. The first experiments to characterize the effect of ICP27 on HSV-1 gene 
expression were transient expression assays and phenotypic studies of ICP27 
temperature-sensitive mutants (6, 9). Subsequent work with viruses having deletions of 
the ICP27 gene showed that ICP27 is needed for robust expression of many DE and L 
genes (11, 69, 70). However, not all DE/L genes require ICP27 for their expression. One 
gene that appears to be expressed independently of ICP27 is ICP8 (11). Further work by 
the Knipe lab determined that other early genes including UL5 are expressed at near 
normal levels in the absence of ICP27 (11). This may explain why measurable levels of 
viral DNA replication (~10% of the wild-type level) occur in ICP27 deletion mutant 
infections (6, 11).  
Functions: mRNA export 
Substantial evidence indicates that ICP27 promotes viral gene expression by serving as 
an export factor for intronless viral mRNAs. Ordinarily, cellular mRNAs require splicing 
before they can be exported to the cytoplasm via the cellular mRNA system, which uses a 
central export factor known as TAP/NXF1. Specifically, a protein complex called the 
transcription export complex (TREX) binds the 5’ end of mRNAs during splicing. 
Aly/REF, a mRNA export adaptor that binds RNA and interacts with mRNA export 
receptor TAP/NXF1, is a constituent of the TREX complex. This complex is required for 
binding of mRNA to TAP/NXF1.  
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 A role for ICP27 in mRNA export in HSV-1-infected cells was first suggested by 
in vivo UV irradiation studies which showed that ICP27 could be cross-linked to poly 
(A)+ RNA in both the nucleus and the cytoplasm (66). Further experiments showed that 
ICP27 interacts with both Aly/REF and TAP/NXF1, thus giving intronless mRNAs 
access to the mRNA export system (19, 20, 63, 66, 71–74). Some data suggest the 
interaction with TAP/NXF1 requires an intramolecular head-to-tail interaction between 
ICP27's N- and C-terminal regions (68, 75). The prevailing model for ICP27's role in 
mRNA export is that the RGG box domain of ICP27 allows it to bind to intronless viral 
mRNAs in the nucleus, and that its interactions with Aly/REF and TAP/NXF1 facilitate 
the escort of these mRNAs from the nucleus (60, 61, 63, 66, 72, 76).  
Functions: inhibition of mRNA splicing 
 Sandri-Goldin's lab initially reported that mRNA splicing is inhibited in HSV-1 
infected cells, and that ICP27 is required for this effect (77). The majority of HSV-1 
mRNAs are intronless, providing a rationale for why the virus may have evolved to 
suppress splicing (66). The mechanism by which ICP27 inhibits splicing is not fully 
understood. Splicing is known to be a highly regulated process that involves various 
RNA-RNA and RNA-protein interactions that occur at sequences on both the 5’ and 3’ 
splice sites, at the branch site, and within the exon itself (78). ICP27 may alter splicing 
through its ability to bind to the essential splicing factor SAP145 (73). This study also 
showed that that ICP27 colocalizes with SAP145 and provided evidence that  splicing  is 
inhibited prior to the initial catalytic step. ICP27 also interacts with the RNA splicing 
regulator p32, and this interaction could be important for splicing inhibition (74). 
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Additionally, ICP27 binds to a number of members of a family of serine-arginine-rich 
splicing factors referred to as SR proteins (73, 77, 79, 80). These proteins have many 
functions and play a particularly important role in spliceosome assembly (78). These SR 
proteins are regulated by phosphorylation and dephosphorylation. ICP27 has also been 
shown to recruit a cytoplasmic SR protein-specific kinase, SRPK1, to the nucleus to 
induce aberrant phosphorylation of SR proteins (79). It was proposed that this stalls 
spliceosome assembly.  
Functions: mRNA stabilization 
 As mentioned earlier, cellular mRNAs are degraded during HSV-1 infection due 
to the action of the vhs viral RNase. However, there is some evidence that ICP27 also 
affects mRNA stability. Specifically, there is evidence that it binds to certain cellular 
mRNA transcripts that contain AU-rich elements (AREs) to stabilize them and prevent 
their degradation (20, 81). AREs have been discovered in several different mRNAs that 
code for inflammatory cytokines, transcription factors and growth factors. AREs promote 
rapid mRNA degradation and regulate translation (82). Ordinarily these transcripts are 
degraded rapidly but various factors such as proinflammatory cytokines and some types 
of viral infections lead to activation of the p38/MAPK pathway, which is known to 
stabilize ARE-containing transcripts by inhibiting their deadenylation (45, 82). Work in 
our lab using a doxycycline-inducible promoter system in HeLa cells determined that 
ICP27 expression alone is capable of inducing p38 signaling to levels comparable to 
those observed in wild-type HSV-1 infection (83).  Thus, ICP27's effects on mRNA 
stability could be indirect, via its ability to stimulate p38 signaling. 
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Functions: interaction with RNA Pol II 
 The cellular RNA polymerase II holoenzyme is a large multisubunit complex 
comprised of  the core RNA polymerase II and general transcription factors including 
TFIIB, TFIIE, TFIIF, and TFIIH (84). The core enzyme has sites for DNA-binding, 
RNA-binding, and catalysis and is expressed in all eukaryotic cells. It contains a region 
essential for cell viability known as the carboxyl-terminal domain (CTD), which consists 
of 52 tandem repeats of heptapeptide consensus sequence YSPTSPS. ICP27 binds the C-
terminal domain of RNA polymerase II and both the N and C termini of ICP27 are 
required for this interaction (85, 86). The Knipe lab suggested that the interaction 
between ICP27 and RNA polymerase II involves RNA because RNase treatment led to 
reduction in coprecipitation with RNA polymerase II (86). However, under some 
conditions this association was resistant to RNase digestion, so they concluded that the 
interaction involves direct protein-protein interaction between ICP27 and RNA 
polymerase II. The Sandri-Goldin lab provided evidence that the interaction between 
ICP27 and RNA polymerase II is essential for recruitment of RNA polymerase II to viral 
replication centers (85). 
Functions: stimulation of viral translation 
There is evidence that ICP27 promotes the translation of some viral mRNAs (87–89). 
Translation involves a number of cellular factors working in concert. Translation 
initiation is facilitated by assembly of the eukaryotic initiation factor 4F (eIF4F) which 
consists of the m7G cap-binding protein eIF4E, scaffold and ribosome adaptor eIF4G, and 
the RNA helicase eIF4a located at the m7G cap (90). The cytoplasmic polyadenylate-
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binding protein (PABP), by binding the poly(A) tail on mRNA, is also a key factor. 
PABP1, via bridging eIF4G and poly(A), may facilitate m7G cap-poly(A) translation 
initiation (88). Interestingly, ICP27 co-precipitates with cellular translation initiation 
factors, PABP1, eIF3 and eIF4G (91). Larralde et al. also provided evidence of ICP27 
interaction with polyribosomes (98). The ability for ICP27 to associate with 
polyribosomes suggests it has a functional role in mRNA stability or translation (92). 
Larralde et al. tested this interaction further in vivo in Xenopus oocytes using a tethered 
function assay to exam the effect of ICP27 on translation in vivo (92). They observed that 
ICP27 was sufficient to directly stimulate the translation of certain mRNAs and that it did 
not require other viral factors to achieve this effect. Larralde et al. also suggested that the 
ICP27 C-terminus was essential for translation stimulation. Finally, ICP27 was also 
shown to assist translation of the viral mRNA encoding the tegument protein VP16 (89, 
93). The stimulation of VP16 translation was mapped to the C-terminus of ICP27, which 
is an area known to bind a variety of translation initiation factors.  
Functions: modulation of interferon responses 
ICP27 also plays a role in modulating the immune response. Type I interferon (IFNα/β) 
signaling is an immune antiviral mechanism and IFNα/β binding of IFNAR-1 and 
IFNAR-2 receptor subunits leads to heterodimerization and phosphorylation of these 
subunits (94). Activation leads to phosphorylation of Jak-1 and Tyk-2 which then 
phosphorylate signal transducers and activators of transcription (STATs) 1 and 2. These 
heterodimerize and translocate to the nucleus and associate with IRF-9, which enables 
them to bind to a cis-acting DNA element referred to as the interferon stimulated 
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response element, ISRE. This interaction leads to the transactivation of interferon-
stimulated genes (94) ). ICP27 has been observed to downregulate STAT1 
phosphorylation and prevent STAT1 accumulation in the nucleus (95, 96). ICP27 
prevents STAT1 nuclear accumulation by inducing the expression of an unidentified 
small type interferon antagonizing protein (95, 96). The mechanism by which ICP27 
regulates STAT1 phosphorylation and its induction of the small antagonizing protein 
remain to be elucidated. 
Functions: activation of MAPKs 
 HSV-1 has been shown to stimulate the pathway of p38 and c-Jun mitogen-
activated protein kinases (MAPKs) and ICP27 has been implicated in this stimulation 
(97). MAPKs are one of the cells pathways that respond to extracellular stimuli and both 
the c-Jun N-terminal kinase (JNK) and the p38 MAPK pathways are categorized as 
extracellular signal regulated kinases (98). The p38 and JNK pathways have both been 
found to be activated as early as 3 hpi by HSV-1, with peak activity at 6 to 8 hpi (83, 99). 
When these pathways are pharmacologically inhibited, HSV-1 viral yields are decreased, 
which suggests that these pathways are important for viral replication (83). The N-
terminus of ICP27 is essential for the interactions with these pathways (83). Our lab has 
determined that ICP27 expression alone is sufficient for p38 activation, even in the 
absence of viral infection (83). 
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Inhibition of apoptosis by ICP27.  
 HSV-1 infection modules the apoptotic pathway in a myriad of ways to both 
induce and even prevent apoptosis during infection. Aubert et al. determined that DE and 
L gene expression was essential for apoptosis prevention (18). Aubert et al. found that 
HEp-2 cells infected with an ICP27 deletion mutant underwent apoptosis, suggesting that 
ICP27 blocks apoptosis in infected human cells (100). To further delineate which 
functions of ICP27 were essential to block infection-induced apoptosis, Aubert et al. 
tested several ICP27 mutant viruses (18). The N-terminus contains the protein’s RNA 
binding and nuclear/nucleolar localization sites, while the C-terminus contains regions 
that are required to enhance expression of later viral gene products. Sequences in both the 
N- and C-terminal segments of ICP27 were required to prevent apoptosis in HEp-2 cells 
(18). Aubert et al. proposed a model for an indirect antiapoptotic role of ICP27 in the 
viral life cycle through its ability to upregulate early and late antiapoptotic viral gene 
products (101). 
Important functional sequences and domains in ICP27 
 Fig. 1 shows the identified functional regions of the ICP27 protein. ICP27 has 
several domains at its N-terminus that facilitate various functions including a nuclear 
localization signal (NLS), nuclear export signal (NES), a RGG box, and an acidic region 
(76). The C-terminus has three conserved herpesvirus domains. The C-terminus is 
required for its essential functions (102).  
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Statement of Thesis Question 
 To date most of the genetic studies focused on ICP27 have used the African green 
monkey kidney Vero cell line (21, 57, 68, 75, 76, 83, 95, 96, 103–107). These cells yield 
very high HSV-1 titers and the virus readily forms plaques on these cells. Vero cells are 
considered to be of epithelial origin, but they display fibroblastic properties (108–110). 
They are an immortal, non-transformed  cell line that is IFN-β deficient (111). One 
paramount issue to consider is that because the virus can disseminate in the body, HSV-1 
can potentially replicate in many cells other than epithelial cells. This raises the question 
of whether the phenotypes of ICP27 mutants are the same in other types of cultured cells.  
This is important because the function of ICP27 in many cases is inferred from the 
phenotype of viral mutants. Thus, in this work we set out to ask whether the replication 
ability of HSV-1 ICP27 mutants is the same in other types of cultured cells as it is in 
Vero cells.  
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MATERIALS AND METHODS 
Cells, Viruses, Infections 
 The cell lines Vero, V27, CV-1, HEK293, U373, U2-OS, ARPE-19, HeLa, and 
HEp-2 were purchased from American Type Culture Collection or obtained from 
colleagues at the University of Minnesota. V27 cells (8) are Vero cells that have been 
stably transfected with the HSV-1 ICP27 gene. Human foreskin fibroblasts (HFF) and 
HFF-TERT (112) were kindly donated by Dr. Wade Bresnahan. TE286 are primary 
human tonsillar fibroblasts and were kindly donated by Dr. Peter Southern. Cells were 
grown in Dulbecco-modified Eagle medium containing 5% or 10%, depending on the cell 
line, heat-inactivated fetal calf serum (FCS), 50 U/ml penicillin, and 50 µg/ml 
streptomycin. The medium for V27 cells was the same, except that it also contained 300 
µg/ml G418.  All tissue culture reagents were purchased from Life 
Technologies/Invitrogen (Carlsbad, CA) except FCS, which was purchased from Atlas 
Biologicals (Fort Collins, CO).  
 The wild-type (WT) HSV-1 strain used was KOS1.1. The ICP27 mutants used 
were d1-2 and d27-1 and their construction has been described (8, 70, 76). The 
multiplicity of infection (MOI) used in experiments was 10 or 1 PFU per cell, as 
indicated. Infections were performed in phosphate-buffered saline (PBS) containing 0.1% 
glucose and 0.1% heat-inactivated newborn calf serum. Viral adsorption was for 1 hr at 
37oC, after which time the viral inoculum was replaced with 199 medium containing 1% 
heat-inactivated newborn calf serum, 50 U/ml penicillin, and 50µg/ml streptomycin. 
Infections were then incubated at 37oC. Infections destined for plaque assay analysis or 
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immunofluorescence were carried out in 12-well trays, while all other infections were 
carried out in 25 cm2 flasks. 
 In the event that infections were to be analyzed via plaque assay, they were 
allowed to incubate for 72 hours before being processed. Processing consisted of removal 
of 199 media; permeabilization and fixation with methanol for 10 minutes; staining with 
1% Giemsa stain (Sigma Aldrich) for at least 1 hr; rinsing of trays with DI water; and 
drying of trays overnight before analysis. Plaques were counted visually with the aid of a 
microscope and the counts were used to calculate the viral titer. 
Plasmid Construction 
 Plasmids having specified mutations in a segment of the ICP27 gene were 
purchased from Genescript. The plasmids containing deletions were pLS12-20, pLS12-
42, pLS43-63, pLS21-63, pLS21-42, and pLS12-63, with the numbers indicating the 
range of amino acid residues deleted from the N-terminus of ICP27.  Plasmids that 
contained substitution mutations in the ICP27 gene were p15LSD-3A, p19DLD-3A, and 
p20L-A. The mutated ICP27 sequences were then introduced into the ICP27 gene on 
plasmid pBH27 via the following strategy. Both the mutant and the pBH27 vector were 
digested for 2 hours at 37oC with AgeI and DraIII. These digests were then run on a 1% 
agarose gel and after band separation, bands corresponding to the desired insert sizes 
were excised from the gel and purified using a Qiagen DNA purification kit as per the 
manufacturer’s instructors. The DNA concentration was determined via use of a 
Nanodrop spectrophotometer. Purified insert DNA containing the mutation was then 
ligated to the purified pBH27 vector backbone. The ligation products were then used to 
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transform competent DH5α E. coli and individual transformants were picked and grown 
overnight on a shaker at 37oC. DNA was obtained and purified from these transformants 
using a ProMega PureYield Plasmid Midiprep System kit. This purified transformant 
DNA was then digested for 2 hours at 37oC with AgeI and DraIII. These digests were ran 
on a 1% agarose gel and plasmids with the desired structure were isolated.  
Protein Analysis 
 Isolation of protein samples and immunoblotting were performed as described 
previously (17). The primary antibodies used were mouse monoclonal antibodies to ICP0 
(H1112), ICP27 (H1113), gD (H1103), ICP4 (H1114), and ICP8 (H1115) and were 
obtained from the Rumbaugh-Goodwin Institute for Cancer Research (Plantation, FL). 
ICP0, ICP27, gD, ICP4, and ICP8 antibodies were used at dilutions of 1:1,000, 1:1,000, 
1:3000, 1:5000, and 1:300 respectively. VP5-specific mouse monoclonal primary 
antibody was obtained from Abcam (Cambridge, MA) and used at a dilution of 1:3200. A 
mouse monoclonal antibody specific to β-actin was purchased from Abcam (Cambridge, 
MA) and diluted 1:10,000. The secondary antibody used for immunoblot detection was a 
horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G, purchased from 
Jackson Immunoresearch (West Grove, PA) and was diluted 1:7500 in phosphate-
buffered saline. Secondary antibodies were detected with enhanced chemiluminescence 
detection reagents as per the manufacturer’s specifications (Amersham).  
RNA Analysis 
 Analysis of RNA via northern Blotting was conducted as described previously 
(76).  Briefly, total RNA of infected cells was harvested at 7 hpi using Trizol (Life  
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Technologies) according to the manufacturer’s instructions. RNA was quantified and 
then run on a 1.5% agarose glyoxal gel as per the manufacturer’s directions. RNA was 
transferred to a nylon membrane and then probed for ICP8 mRNA using radioactively-
labeled plasmid pE/3583 (113) (ICP8 probe). Finally, the radioactive signal was 
visualized by autoradiography. 
Immunofluorescence  
 Cells plated on coverslips were fixed in 3.7% formaldehyde in phosphate-
buffered saline for 10 min, followed by cold (-20oC) acetone permeabilization for 2 min. 
For fluorescent staining, coverslips were incubated at 37oC for 1 hr with one of two 
different primary antibodies. Primary antibodies used were a monoclonal mouse ICP4 
(H1114) antibody (1:800) and a monoclonal mouse ICP27 (H1113) antibody (1:300). 
Both antibodies were diluted in PBS. The secondary antibody used was a Dylight 488-
conjugated Affinipure Fab fragment Goat anti-mouse IgG(H+L) from Jackson 
Immunoresearch Laboratories diluted 1:300 in PBS. The secondary was also diluted in 
phosphate-buffered saline. Nuclei were stained with DAPI, which is a component of the 
mounting medium used (Fluoroshield, Sigma-Aldritch). Cells were examined using a 
confocal fluorescent microscope (Olympus Fluoview FV1000 BX2) linked to a video 
camera. Images were captured as TIFF files using the program Olympus Fluoview. 
Virus Complementation Experiments 
 Subconfluent 25 cm2 flasks of HEp-2 or Vero cells were transfected with 7.5 μg 
of ICP27-encoding plasmid using Lipofectamine 2000 (Invitrogen). At 24 hrs post 
transfection, cells were infected at an MOI of 1 with the ICP27-null mutant d27-1. At 2 
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hpi, flasks were subjected to an acid-glycine low pH wash step to inactivate any 
remaining extracellular virus. This step significantly decreased the virus background in 
this assay. Infections were then incubated at 37oC for 24 hrs. Infections were terminated 
by adding 5 mL of sterile non-fat dry milk. Viral yield was determined by plaque assay 
analysis on V27 cells. Virus was released by three cycles of freeze thawing.  
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RESULTS 
 ICP27 mutant d1-2 displays a cell-type dependent growth defect. Most 
previous analyses of ICP27 mutants have been carried out in Vero cells, an epithelial cell 
line originally isolated from African green monkey kidney tissue. Vero cells have been 
used extensively in HSV-1 research, in part because the virus replicates quite robustly in 
these cells and readily forms plaques on them. To see if ICP27 mutants grow similarly in 
a different cell type, we used HeLa cells, a transformed line of human cervical epithelial 
cells which have also been used in HSV-1 work. As mutations in the C-terminal half 
abrogate most or all of ICP27's functions (102), we focused on mutants having short in-
frame deletions in the N-terminal half of the ICP27 gene (Fig. 1) (65, 70, 76). Although 
some of these mutants are deficient for growth in Vero cells, they all replicate 
significantly greater than an ICP27 null mutant. To carry out the analysis, HeLa cells 
were infected at an MOI of 10 PFU/cell with WT HSV-1 or ICP27 deletion mutants and 
incubated for one day before being harvested. The amount of infectious progeny in each 
culture lysate was then determined by plaque assay on ICP27-complementing V27 cells 
(8) (Fig. 2A). The results showed that, with one exception, all mutants exhibited yields 
that are roughly comparable to that previously seen in Vero cells (see Fig. 1). The 
exception was d1-2, which has a deletion of codons 12-63. In Vero cells, this mutant 
shows a 10-100-fold replication defect, but in HeLa cells it is much more restricted, 
exhibiting a near 100,000-fold defect.  
 To confirm this finding, we next directly compared the growth of d1-2 in HeLa 
and Vero cells. We also included dAc, an ICP27 mutant that has a smaller deletion in the 
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same region of the ICP27 gene (codons 20-63) (Fig. 1). The results (Fig. 2B) confirmed 
that d1-2 replicates much more poorly in HeLa cells than it does in Vero cells. In 
contrast, dAc replicated similarly to the WT virus in both HeLa and Vero cells. 
Importantly, an independent isolate of d1-2, d1-2b (70), showed the same growth 
phenotype as d1-2 (data not shown), demonstrating that the inability of d1-2 to replicate 
in HeLa cells is not due to a secondary mutation, but rather results from the engineered 
ICP27 gene deletion. 
 To see if the growth restriction of d1-2 is limited to HeLa cells, we tested its 
growth in another human line, HEp-2 cells. The results (Fig. 2C) resembled those seen in 
HeLa cells, i.e., the growth of d1-2 was highly restricted.  In this case, the results were 
even more dramatic, in that d1-2 replicated >10,000-fold less efficiently in these cells 
than in Vero cells. In contrast, dLeu and dAc showed only modest reductions in viral 
growth in HEp-2 cells compared to Vero cells. In summary, these results show that the 
ICP27 mutant d1-2 has a cell type-dependent growth phenotype, as it replicates 
considerably more poorly in HeLa and HEp-2 cells than it does in Vero cells. Amongst 
our collection of ICP27 N-terminal mutants, we did not identify any other ICP27 mutant 
with this same high degree of cell-type dependent replication. 
 Identification of other host cells that are highly restrictive for d1-2 
replication. It is possible that the very poor replication of d1-2 in human HeLa and HEp-
2 cells compared to monkey Vero cells is due to the species origin of the cells. However, 
there are several other differences between HeLa/HEp-2 and Vero cells. To understand 
the cellular factors that contribute to the cell-specific replication phenotype of d1-2, we 
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surveyed a variety of cell lines and primary cell cultures (Table 1) for their ability to 
serve as hosts for d1-2. Each cell line was infected in triplicate at an MOI of 10 with WT 
HSV-1 (KOS1.1), d27-1 (an ICP27 null mutant) or d1-2, and the infections were 
incubated for 24 hrs. The final viral yields were determined by plaque assay on V27 cells. 
The data are shown in Fig. 3. WT HSV-1 replicated quite well (>2 x 106 PFU/ml) in all 
the cell lines, while d27-1 completely failed to replicate in any of them (<1 x 101 
PFU/ml). In contrast, the replication of d1-2 fell into two clear categories. Of the eleven 
cell lines/primary cell samples tested, four (Vero, CV-1, ARPE19, and 293) were semi-
permissive, that is capable of supporting a modest level of d1-2 replication (>2 x 103 
PFU/ml). The other seven were restrictive, failing to support any replication (<1 x 101 
PFU/ml). Examination of the data with respect to cell type failed to reveal a simple 
correlation between the ability of d1-2 to replicate and the species, tissue origin, or 
transformation status of the host cells. 
 Viral replication compartment formation is highly deficient in d1-2 and d27-
1 infected HEp-2 cells. The fact that d1-2 can replicate in some cells but not others 
suggest that an ICP27 function (or functions) defective in d1-2 is more important in 
certain cells than in others. However, it is not known what this function is. To provide 
some insight into this, we set out to determine why d1-2 completely fails to replicate in 
restrictive cells. In all experiments, we compared d1-2 infections in HEp-2 cells to those 
in Vero cells, where d1-2 can replicate, albeit semi-permissively. 
 One possibility for the restriction of d1-2 in HEp-2 cells is that ICP27 is 
expressed very poorly or is localized aberrantly. To test these possibilities, we used 
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immunofluorescence microscopy to examine ICP27's expression and localization. Thus, 
Vero and HEp-2 cells were infected with d1-2 at an MOI of 10. As controls, we also 
mock-infected cells, or infected them with KOS1.1 or d27-1. The cells were fixed and 
permeabilized at 4 and 8 hpi and subjected to immunofluorescence using a monoclonal 
antibody to ICP27 (Fig. 4). The results showed that d1-2 expresses ICP27 with WT 
kinetics in both HEp-2 and Vero cells. Additionally, at 4 hpi, d1-2 encoded ICP27 protein 
localizes similarly to WT protein, being strongly nuclear with a somewhat heterogenous 
distribution. At 8 hpi, d1-2 ICP27 showed a much more compartmentalized distribution 
than WT ICP27. However, as this was observed in both the Vero and HEp-2 cells, this 
localization cannot explain the total failure of d1-2 to replicate in HEp-2 cells. This 
experiment indicates that the inability of d1-2 to replicate in HEp-2 cells is not due to a 
lack of expression of ICP27 or to a grossly altered localization in the cell. 
 We next examined the expression and localization of another IE protein, ICP4. 
ICP4 is an essential transcription factor that is required for the expression of nearly all 
DE and L genes. Early in infection (2-4 hpi), ICP4 localizes diffusely in the nucleus, but 
as infection proceeds, it begins to accumulate in globular structures know as viral 
replication compartments (RCs) (114). RCs are sites of viral DNA replication and 
possibly late gene expression, and their formation is dependent upon viral DNA 
replication (114). To examine ICP4 localization, HEp-2 or Vero cells were mock-infected 
or infected with WT, d27-1, or d1-2. The cells were fixed at 4 and 8 hpi and processed 
for ICP4 immunofluorescence (Fig. 5). At 4hpi, ICP4 was expressed in all the infections 
and the localization patterns were similar, irrespective of virus or host cell. At this time 
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point, ICP4 exhibited a diffuse nuclear localization with some additional staining in small 
nuclear punctae. However, at 8 hpi, clear differences in ICP4 staining emerged. In the 
case of the WT virus, ICP4-containing RCs were clearly seen in numerous Vero and 
HEp-2 cells (white arrows in Fig. 5). In the d1-2 infection of Vero cells, RCs were also 
frequently observed, although only in a minority of the infected cells. However, in d1-2-
infected HEp-2 cells, viral RCs were almost never observed. Interestingly, similar 
findings were seen in the d27-1 infections, in that nuclear RCs were frequently observed 
in Vero cells, but not in HEp-2 cells. A repeat experiment wherein the staining was 
performed at 12 hpi yielded a similar result (data not shown), i.e., RCs for d1-2 and d27-1 
were seen in Vero but not HEp-2 cells.  
 The presence of replication compartments in Vero cells is not surprising as 
several studies have shown that in d1-2 and d27-1 infected cells, viral DNA is replicated 
in the absence of ICP27, although overall this results in low levels of replication such that 
DNA replication is reduced 60-90% (6, 8).  The almost complete lack of RCs in d27-1-
infected HEp-2 cells suggests that ICP27 is more critical for viral DNA replication in 
HEp-2 cells than it is in Vero cells. Moreover, these results suggest that d1-2 is unable to 
replicate significant amounts of viral DNA in HEp-2 cells.  
 ICP8 expression is deficient in d1-2-infected HEp-2 cells. Viral DNA 
replication is dependent on the induction of viral DE gene expression by the IE proteins. 
In particular, viral DNA replication is contingent upon expression of seven viral proteins 
that collectively make up the core viral DNA replication machinery. These consist of a 
single-stranded DNA-binding protein (ICP8), an origin-binding protein (UL.9), a two-
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subunit viral DNA polymerase (UL30 and UL42), and a three-subunit helicase-primase 
complex (UL5, UL8, and UL52).  To examine the expression of viral DE and L genes in 
d1-2-infected cells, we carried out an immunoblotting analysis. HEp-2 or Vero cells were 
mock-infected or infected at an MOI of 10 PFU/cell with KOS1.1, d1-2 or d27-1. Total 
protein extracts were prepared at 4, 8 and 12 hpi and subjected to immunoblotting using 
antibodies specific for ICP27, two DE proteins (glycoprotein D and ICP8), and an L 
protein (VP5) (Fig. 6). For ICP27, the results of this were consistent with the 
immunofluorescence experiments (Fig. 4) in that d1-2 was able to induce ICP27 
expression similarly to the WT virus in both Vero and HEp-2 cells (note that the ICP27 
molecule encoded by d1-2 migrates more rapidly than the WT protein as a result of its 
deletion). The induction of the gD protein was clearly deficient in d27-1-infected cells, 
indicating that its expression is ICP27-dependent. However, d1-2 was able to induce this 
gene efficiently in both Vero and HEp-2 cells, indicating that d1-2 is not greatly deficient 
in the ICP27 function needed for induction of this gene. The results for DE protein ICP8 
were quite different, however. As has been previously reported, ICP8 induction was not 
ICP27-dependent in Vero cells (11). However, its expression was heavily dependent 
upon ICP27 in HEp-2 cells, as d27-1-infected cells showed a delay and reduction in ICP8 
accumulation. Moreover, d1-2 closely resembled d27-1 in its ICP8 expression.  Finally, 
we examined the expression of the L protein VP5. VP5 expression was dependent on 
ICP27 in both Vero and HEp-2 cells, based on the reduction in VP5 accumulation seen in 
the d27-1 infection. However, in both Vero and HEp-2 cells, d1-2 was able to express 
significantly more VP5 than d27-1, although the levels were still reduced compared to the 
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WT infection. These results indicate that the mutation in d1-2 weakens the function 
needed for VP5 expression.  
 Another experiment was conducted to determine whether ICP8 levels are reduced 
in d1-2 infections of other non-permissive cells. Thus, we infected restrictive cells, HFF, 
and a semi-permissive line, ARPE-19. Total proteins were harvested at 8 hpi, and 
analyzed for ICP8 expression by immunoblotting (Fig. 7). ICP8 protein expression levels 
were decreased in the d1-2 infected HFF cells, but not in d1-2 infected ARPE-19 cells. 
Thus, in the restrictive cells (HEp-2 and HFF) ICP8 expression is dependent upon ICP27, 
and does not occur efficiently in the d1-2 mutant. This indicates that the deletion in d1-2 
weakens an ICP27 function that enhances ICP8 expression in HEp-2 and HFF cells.  
 ICP8 mRNA expression is decreased in d1-2 infected HEp-2 cells. In order to 
ascertain at which point in the gene expression pathway ICP8 protein levels were being 
reduced, we examined the expression of ICP8 mRNA. We infected either Vero or HEp-2 
cells at an MOI of 10 with KOS, d1-2 and d27-1 and purified total RNA at 7 hpi. Equal 
amounts of the RNA were subjected to Northern blot analysis using a radioactive probe 
that binds to the ICP8 transcript (Fig. 8).  In Vero cells, ICP8 mRNA levels were not 
dependent on ICP27, as has been noted before. However, in HEp-2 cells, both d1-2 and 
d27-1 displayed a significant decrease in ICP8 transcript levels. Thus, in HEp-2 cells, 
ICP8 mRNA expression is dependent on ICP27, and d1-2 is defective in the ICP27 
function need to induce ICP8 mRNA expression.  
 ICP27 residues 12-20 are essential for viral replication in HEp-2 cells. The 
above results indicate that ICP27 residues 12-63 are absolutely essential for viral 
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replication in HEp-2 cells, although in Vero cells, they are not required for a significant 
level of viral growth. To narrow down the N-terminal residues involved in this cell-
specific difference, we took advantage of the fact that plasmids expressing a cloned 
ICP27 gene can complement the growth of an HSV-1 ICP27 deletion mutant (8). 
Therefore, we constructed various ICP27 mutant plasmids that had a deletion or point 
mutations in the N-terminal region of ICP27 (Fig. 9) and asked whether transfection of 
the cloned genes into Vero and HEp-2 cells can complement growth of d27-1 (Fig. 10). A 
key mutant was pLS12-63, in which the deletion present in d1-2 was engineered. As 
expected, pLS12-63 significantly complemented d27-1 in Vero cells, but not in HEp-2 
cells (Fig 10A). These results independently verify that the lethal phenotype of d1-2 in 
HEp-2 cells is not due to a secondary mutation. Plasmids pLS12-20 and pLS12-42 gave 
very similar results, i.e. they were completely unable to complement d27-1 in HEp-2 cells 
but were able to partially complement in Vero cells. Further experimentation with 
plasmids pLS21-42 and pLS21-63 indicated that deleted residues C-terminal to residue 
20 does not lead to a lethal mutation in HEp-2 cells (Fig 10B). These results show that 
deletion of amino acids 12-20 leads to a lethal mutation in HEp-2 cells. 
 The above data implicate residues 12-20 as being critical for growth in HEp-2 
cells. However, virus mutant dLeu, which lacks residues 6-19 (Fig. 9) grows to a 
significant extent in Vero cells. We therefore hypothesized that the sequence around 
residue 20 is a critical for growth in HEp-2 cells. To test this, we generated three ICP27 
gene mutants that have point mutations at or near residue 20. 15LSD-3A has a triple 
alanine-substitution at residues 15-17, 19DLD-3A has a triple alanine-substitution at 
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residues 19-21, and 20L-A has a single alanine substitution at residue 20. When those 
mutants were tested in the complementation assay (Fig. 10D) 15LSD-3A, 19DLD-3A 
and 20L-A plasmids complemented the growth of d27-1 in both HEp-2 and Vero cells. 
However, the level of complementation differed significantly between cell lines. A 
student’s T-test revealed that there was a statistically significant difference between the 
ability of the 19DLD-3A plasmid to complement d27-1. This difference was observed in 
both cell lines but was most significant (p-value <.0001) in the HEp-2 cell line. Thus, 
although 19DLD-3A is not a lethal mutation, it does lead to a cell-type dependent 
phenotype.  
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                                             DISCUSSION  
 The replication of ICP27 mutant d1-2 depends on the identity of the host cell. 
 In this work, we identified HSV-1 ICP27 mutant d1-2 as one that has a cell type-
dependent growth phenotype, in that it replicates in Vero cells, albeit somewhat 
inefficiently, but is completely unable to replicate in HEp-2 cells. To explore the nature 
of this defect, we characterized the growth of d1-2 in a large panel of different cells 
(Table 1). The cells were chosen with regard to a number of different factors that could 
potentially be important for this phenotype. These include cell type, transformation 
status, and species origin. The results (Fig. 3) indicated that more than half of the cell 
lines or strains tested failed to support any d1-2 replication, while a few supported a 
significant amount of replication. Thus, the cells fell into two clear categories with 
respect to d1-2 replication. We failed to observe a correlation between the replication 
phenotype of d1-2 and the transformation status of the cells, as both primary cells (HFF, 
HFF-Tert, and TE286) and cancer cell lines (HeLa, HEp-2, U2-OS, U373) were 
restrictive for d1-2 growth. We were also able to rule out species origin as being critical 
to the phenotype, as two human cell lines (293 and ARPE19) and two monkey cell lines 
(Vero and CV-1) were semi-permissive for d1-2 growth. Additionally, the cell type did 
not appear to play a role, since we did not observe a correlation between cell type and 
restrictiveness. Human fibroblasts are a natural host cell of HSV-1 but were restrictive for 
d1-2 growth, while Vero cells, the model cell system for HSV-1 research, were semi-
permissive.  
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 With these results in mind, we suggest that Vero cells are not the best model of 
natural infection as they are not derived from the natural host for HSV-1 and they yield 
different results than cells which are. Our work thus emphasizes that cell type is a critical 
factor in studying HSV-1, particularly in regard to ICP27 function.  
 The data from these experiments suggests that one or more of ICP27 functions in 
HSV-1 infection is dependent on an as yet unknown factor (or factors) present in some 
cells but not others. There are two general possibilities for this. First, semi-permissive 
cells could express a factor that carries out a replication function that is lacking in the d1-
2 ICP27 molecule. In this model, restrictive cells would lack that factor. Alternatively, 
restrictive cells could express a restriction factor that inhibits HSV-1 replication in the 
absence of the missing ICP27 function. In this model, semi-permissive cells would lack 
that factor. One experimental approach that may elucidate which of these models is 
correct is a host gene expression microarray analysis of d1-2 infected restrictive and 
semi-permissive cells. This might allow us to identify host  genes that are up- or down-
regulated during d1-2 infection in a manner that is correlated with the semi-permissive or 
restrictive nature of the infection. If so, such genes could be targeted by siRNA 
knockdown to test the role that the gene plays in replication under various conditions.  
 Identification of a short sequence in ICP27 that determines cell type-specific 
growth. The d1-2 mutant has a deletion of codons 12-63, indicating that the N-terminal 
region of ICP27 is critical for the host-range dependent phenotype. To home in on the 
most critical residues for this phenotype, we created various ICP27 deletion mutant gene 
constructs with shorter deletions in the region encompassing residues 12-63 (Fig. 9A). 
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These plasmids were then used in transfection-infection experiments to see which mutant 
genes supported the growth of an ICP27 deletion mutants in HEp-2 and Vero cells. We 
observed that deleting a 9 amino acid region, corresponding to residues 12-20, was 
sufficient to reproduce the replication defect of d1-2. (Fig. 10B). To study the relevant 
sequences further, we also engineered three plasmids encoding ICP27 molecules with 
point mutations in the region of interest. Of these, mutant 19DLD-3A was the only 
plasmid that resulted in a phenotype that resembled d1-2, i.e., it led to significantly less 
growth in Vero cells compared to HEp-2 cells (Fig. 9B). Thus, this mutant indicates that 
residues 19-21 are very important in the cell type-dependent replication phenotype. 
Future mutagenesis experiments should focus more intently on this region, both through 
deletions and substitution mutants. 
What is the block to replication in d1-2 infected HEp-2 cells? We performed 
several experiments to understand why d1-2 is completely unable to replicate in HEp-2 
cells. First, we examined the expression and localization of the d1-2 ICP27 protein. The 
ICP27 in d1-2 infections of both Vero and HEp-2 cells at 8hpi displayed a similar 
aberrant localization pattern which suggests that the abnormal localization cannot 
completely explain the failure of d1-2 to replicate in HEp-2 cells (Fig. 4). Second, we 
examined replication compartment formation as these structures are essential for HSV-1 
DNA replication. Interestingly, we observed that replication compartments do not 
efficiently form in d1-2 infections of HEp-2 cells (Fig 5). This suggests that viral DNA is 
not replicated in d1-2-infected HEp-2 cells.  
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 Since viral DNA replication depends on efficient DE protein synthesis, we next 
looked at protein accumulation at 4, 8 and 12 hpi, assaying proteins from all three viral 
gene classes. Of the proteins observed, only L protein VP5 and DE protein ICP8 were 
reduced in expression in d1-2 infected HEp-2 cells (Fig. 6). In the case of ICP8, 
expression was reduced quite significantly. This was unexpected because ICP8 
expression is not dependent on ICP27 in Vero cells (11). We also found that ICP8 
expression is reduced in another restrictive cell setting, HFF cells, but not in semi-
permissive ARPE-19 cells (Fig. 7). Thus, there is a correlation between restrictiveness of 
the cell line for d1-2 growth and ICP8 expression. As ICP8 has been established as being 
essential for HSV-1 DNA replication, these results suggest an explanation for the failure 
of d1-2 to replicate DNA in HEp-2 and other restrictive cells (39).  
 Further investigation by northern blotting analysis revealed that ICP8 mRNA 
transcript expression is dramatically reduced in HEp-2 infections, but in Vero cells is 
only slightly diminished, consistent with work from the Knipe lab (11). Thus, deficient 
ICP8 protein expression in d1-2-infected HEp-2 cells appears to be due to a reduction at 
the level of its encoding mRNA. The level at which ICP27 regulates ICP8 mRNA 
expression in HEp-2 cells is unknown, but it is possible that it increases transcription of 
the ICP8 gene. It is also possible it stabilizes the mRNA, possibly through an effect on 
export of the mRNA.  
 Based on our results, we hypothesize that the reduction of ICP8 mRNA (and 
possibly in mRNA encoding other viral replication proteins) is responsible for the 
precipitous drop in genome replication in non-permissive cells. This would be in contrast 
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to the situation in Vero cells, where ICP27 mutants have diminished DNA replication  
but still replicate their genomes to a significant degree (11-38% of WT levels) (6, 70, 
115). As seven viral gene products are involved in HSV-1 DNA replication, it is 
unknown if other viral replication proteins are similarly reduced in d1-2-infected HEp-2 
cells. One way to address this is to ask whether exogenous expression of ICP8 in a 
restrictive cell line is sufficient to rescue the replication of d1-2. If so, then it would be 
possible to conclude that ICP8 insufficiency is the fundamental defect of d1-2 in HEp-2 
cells. However, it is possible that other critical HSV-1 DE genes are expressed at reduced 
levels, and thus ICP8 alone would be unable to rescue the phenotype.  
 It should be pointed out that this work is consistent with work from the Blaho lab 
which indicated that certain ICP27 mutants including d1-2 induce apoptosis at late times 
in HEp-2 and other human cells, but not in Vero cells (100). Analysis of viral gene 
expression in infected HEp-2 cells suggested that this effect was due to the ability of 
ICP27 to stimulate expression of certain early and/or late genes that encode apoptosis 
suppressors (18). Our finding that d1-2 is deficient in early/late gene expression is 
consistent with this. However, as apoptosis occurs late in infection, it is unlikely to 
explain the complete lack of d1-2 growth in HEp-2 cells.  
 Is there a novel HEp-2 specific ICP27 function? ICP27, is a complex, 
multifunctional protein with a number of known functional domains. The region deleted 
in d1-2 includes a portion of the NES as well as the entire acidic region. However, we 
have determined that deletion of amino acid residues 12-20 is sufficient to replicate this 
phenotype. This suggest that there may be another functional domain within this region in 
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addition to the NES that has yet to be identified. Furthermore, it is possible that this 
function may only be required in certain, i.e. restrictive, cells. If so, it may be possible to 
create a mutant that is able to replicate to WT levels in Vero cells but is defective for 
growth in HEp-2 and other human cells. The mutant 19DLD-3A resembles such a 
mutant, although it is slightly defective for replication in Vero cells.  
 Summary and conclusions. The findings presented here show that one or more 
ICP27 functions is cell-type dependent. Specifically, we report that a specific ICP27 
mutant, d1-2, shows a striking cell-type dependent growth defect wherein it replicates 
semi-permissively in monkey Vero cells but is completely restricted for replication in 
several human cells including HEp-2 cells and primary human fibroblasts. The failure of 
d1-2 to replicate in human HEp-2 cells appears to be linked to a reduction in expression 
of ICP8, a key DNA replication factor, at both the transcript and protein level. This 
suggests that expression of viral DE/L proteins are more dependent on ICP27 in certain 
cell lines, including primary human fibroblasts which are a better model of natural 
infections than are Vero cells. As most previous studies of ICP27 function have been 
carried out in Vero cells, our studies highlight the need to carry out future analyses in 
cells that can be considered more relevant to natural HSV-1 infections. 
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Fig. 1. HSV-1 ICP27 mutants. At the top is shown a schematic of the 512-residue 
ICP27 polypeptide, with notable functional sequences highlighted. Below are shown 
representations of the HSV-1 ICP27 N-terminal mutants used in this study. Numbers 
above the deletions indicate amino acids deleted in the various mutant polypeptides. 
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Fig. 2.  Mutant d1-2 replication is more defective in HeLa and HEp-2 cells than in 
Vero cells. (A) Screening of mutants in HeLa cells. HeLa cells were infected in duplicate 
at an MOI of 10, incubated for one day, and harvested. The amount of viral progeny was 
then determined by plaque assay on V27 cells. The bars indicate the means of the 
duplicate infections and the bars denote the range of the two values. (B) Comparison of 
ICP27 mutant growth in HeLa and Vero cells. Details are as in (A), except that infections 
A
B
C
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were carried out in both HeLa (black bars) and Vero cells (white bars). (C) Comparison 
of ICP27 mutant growth in HEp-2 or Vero cells. Details as in (A), except that infections 
were carried out in both HEp-2 (cross-hatched bars) and Vero cells (white bars). 
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Figure 3. d1-2 replication is predominantly non-permissive in cell lines examined. 
The various cells were infected in triplicate with WT HSV-1, the ICP27 deletion mutant 
d27-1, or d1-2 at an MOI of 10 and incubated for one day. The progeny were then 
determined by plaque assay on V27 cells.  Values shown represent mean titers and error 
bars denote standard error. Our limit of detection was 101 PFU/mL as indicated by the 
yellow line.  Indicated samples were considered semi-permissive for d1-2 infection if 
mean viral titers were >100-fold above the limit of detection and non-permissive if not. 
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Figure 4. ICP27 expression and localization appear similar in d1-2-infected Vero 
and HEp-2 cells. Detection of ICP27 in infected HEp-2 and Vero cells was carried out 
using confocal microscopy and an α-ICP27 mouse monoclonal antibody (green). Nuclei 
were stained with DAPI present in the mounting media (blue). Images were collected 
from a single coverslip at 4 and 8 hpi and are representative of expression in other cells 
observed on the coverslip. 
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Figure 5. Replication compartments do not form in d1-2-infected HEp-2 cells. 
Detection of ICP4 in infected HEp-2 and Vero cells was carried out by confocal 
microscopy using an α-ICP4 rabbit monoclonal antibody (green). Nuclei were stained 
with DAPI present in the mounting media (blue). Each image was collected from a single 
coverslip at 4, 8 and 12 hpi and is representative of expression in other cells on the 
coverslip. 
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Figure 6. Expression of viral proteins in d1-2 infections in HEp-2 and Vero cells. 
HEp-2 and Vero cells were infected with KOS, d1-2 and d27-1 at an MOI of 10. These 
samples were then harvested at 4, 8 and 12 hpi. These lysates were then fractionated by 
SDS-PAGE and finally transferred to nitrocellulose. Anti-ICP27, anti-ICP0, anti-ICP4, 
anti-ICP8, anti-VP5 and anti-gD antibodies were used for western blot analysis. β-actin 
levels were determined as the loading control. 
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Figure 7. ICP8 expression in infected HFF and ARPE-19. HFF and ARPE-19 cells 
were infected with KOS, d1-2 and d27-1 at an MOI of 10. These samples were then 
harvested at 8 hpi. The lysates were then fractionated by SDS-PAGE and transferred to 
nitrocellulose. Anti-ICP8 antibodies were used for western blot analysis. HnRNP L levels 
were analyzed as the loading control.   
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Figure 8. ICP8 mRNA levels are reduced in d1-2-infected HEp-2 cells. HEp-2 and 
Vero cells were infected with KOS, d1-2 and d27-1 at an MOI of 10. These samples were 
then harvested at 7 hpi. ICP8 mRNA transcript was detected using P32-labeled probes 
specific for the ICP8 genes. The Millennium RNA markers (Ambion) were used for 
transcript size determination. 
 
 
 
 
 
HEp-2 Vero 
M
o
c
k
 
K
O
S
 
d
1
-2
 
d
2
7
 
M
o
c
k
 
K
O
S
 
d
1
-2
 
d
2
7
 
 
 
46 
 
 
Figure 9.  Map of ICP27 plasmid mutants constructed in this study. 
ICP27 plasmid mutants. Deletions or point mutations were engineered into ICP27 
plasmids as shown. 
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Figure 10.  Complementation of d27-1 replication by mutant ICP27 genes.  (A-D) 
d27-1 complementation experiments. HEp-2 and Vero cells were transfected in triplicate 
with each of the respective plasmids using Lipofectamine 2000. After 24 hrs, the 
transfected cells were infected with d27-1. At 24 hpi, the infected samples were frozen in 
milk and freeze-thawed for viral titering on V27 cells. Values shown represent mean 
titers and error bars denote SEM. The limit of detection in the plaque assay was 10 
PFU/mL. 
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Cells Lethal Tissue Origin Morphology 
Vero*  - 
 
Kidney capsule Epithelial 
CV-1*  - Kidney capsule Epithelial 
ARPE1
9 
- Retina Epithelial 
293 - Embryonic 
kidney 
Epithelial  
HeLa X Cervical 
adenocarcino
ma 
Epithelial 
HEp2 X Larynx 
carcinoma 
Epithelial 
U2-OS X Osteosarcoma Epithelial 
U373 X Glioblastoma Astrocytoid 
TE286 X Tonsil(primary) Fibroblast 
HFF X Foreskin 
(primary) 
Fibroblast 
HFF-
Tert 
X Foreskin 
(primary, 
telomerase 
extended) 
Fibroblast  
 
Table 1. Cells Used in This Study.  Asterisks indicate cells of African Green Monkey 
origin. An [x] in the lethal column indicates that d1-2 in this cell line/primary cell 
sample, while [-] indicates that it does. Morphology and tissue information was obtained 
from the American Type Culture Collection (ATCC) website for each of the cell lines 
obtained from ATCC, while morphology and tissue information for primary cell samples 
was provided by the respective donors of the cells. 
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